Optimal Evaluation of Programmed Death Ligand-1 on Tumor Cells Versus Immune Cells Requires Different Detection Methods
|
|
- Gyles Fitzgerald
- 5 years ago
- Views:
Transcription
1 Optimal Evaluation of Programmed Death Ligand-1 on Tumor Cells Versus Immune Cells Requires Different Detection Methods Kelly A. Schats, PharmD; Emily A. Van Vré, PhD; Carolien Boeckx, PhD; Martine De Bie, BSc; Dorien M. Schrijvers, PhD; Bart Neyns, MD, PhD; Ingrid De Meester, PharmD, PhD; Mark M. Kockx, MD, PhD Context. The benefit of programmed death ligand-1 (PD-L1) immunohistochemistry (IHC) as a method to select patients who may benefit from programmed death receptor-1 (PD-1)/PD-L1 immunotherapies remains uncertain in many tumor indications. Objectives. To compare the commercially available, approved PD-L1 IHC assays (22C3, 28-8, SP142, SP263), specifically identifying the changes in staining output created by altering the detection method. Design. This pilot study investigates the respective PD- L1 kit assay staining patterns and related scoring of tumor cells and immune cells on lung carcinoma and melanoma. Furthermore, the influence of the detection method (platform and related reagents) on PD-L1 antibody performance is studied. Results. The SP142 kit reveals more immune cell staining but less tumor cell staining than the other PD-L1 kits. Alternatively, the 22C3 and 28-8 kits show good tumor cell sensitivity, but less pronounced immune cell staining, even in tonsil. Tumor cell staining by the SP263 kit is comparable to that of 22C3 and 28-8 kits, while immune cell staining is better. Strikingly, the selection of the detection method has a major impact on the sensitivity of the assay for PD-L1 detection per cell type. Switching the detection method of the kits could largely circumvent the observed staining differences. Conclusions. The diverse sensitivities caused by the choice of the detection method should be taken into consideration when selecting PD-L1 kits or developing PD- L1 IHC laboratory-developed tests. When using alternative kits or laboratory-developed tests, it is strongly recommended to reestablish their clinical utility per therapeutic agent or compare them with the original kit. (Arch Pathol Lab Med. 2018;142: ; doi: / arpa oa) Many promising results were obtained by using anti programmed death receptor-1 (PD-1) or anti programmed death ligand-1 (PD-L1) therapy in different tumor types, and several PD-1/PD-L1 blocking agents are already approved by the US Food and Drug Administration (FDA). Some of these are in combination with a companion or complementary PD-L1 immunohistochemistry (IHC) assay, which was developed in parallel with the drug (overview in Table 1). 1,2 However, not all studies showed association between PD-L1 expression and better clinical response. Additionally, the predictive value of PD-L1 cannot easily be compared between different clinical trials, as different PD- L1 IHC assays were used. Therefore, there is an urgent need to perform comparison studies by using the commercially available kits with the prominent PD-L1 antibody clones 22C3, 28-8, SP142, and SP263. The aim of this pilot study is to compare the staining pattern of 4 PD-L1 IHC kits. The assay performance, particularly the sensitivity of PD-L1 antigen detection, was studied on tonsil, a selection of non small cell lung cancer, and metastatic melanoma samples. Accepted for publication October 24, Published as an Early Online Release April 2, Supplemental digital content is available for this article at www. archivesofpathology.org in the August 2018 table of contents. From the Departments of Immunohistochemistry (Drs Schats, Van Vré, Boeckx, and Schrijvers and Ms De Bie) and Molecular Pathology (Dr Kockx), HistoGeneX, Antwerp, Belgium; the Department of Medical Biochemistry, University of Antwerp, Antwerp, Belgium (Drs Schats and De Meester); and the Department of Medical Oncology, Universitair Ziekenhuis Brussel, Belgium (Dr Neyns). MATERIALS AND METHODS KAS, EAVV, CB, MDB, and DMS are employees of HistoGeneX NV. MMK is CEO of HistoGeneX NV, which performs immunohistochemical and molecular testing for pharmaceutical companies as Control and Tumor Tissue part of (preclinical) clinical studies that evaluate new anticancer Formalin-fixed paraffin-embedded tonsil, placenta, and 7 drugs. The authors have no other relevant affiliations or financial melanoma metastasis samples were obtained in accordance involvements with any organization or entity with a financial interest with the Helsinki Declaration of 1975, following patient in or financial conflict with the subject matter or materials discussed privacy procedures and approval by the hospital ethics in the manuscript apart from those disclosed. Corresponding author: Kelly A. Schats, PharmD, HistoGeneX NV, committee (EC/PC/avl/ and CME 2010/266). Two Prinses Josephine Charlottelaan 10, 2600 Antwerp, Belgium ( additional non small cell lung cancer (1 adenocarcinoma kelly.schats@histogenex.com). and 1 squamous cell carcinoma) and 2 melanoma resection 982 Arch Pathol Lab Med Vol 142, August 2018 Different Detection Methods for Evaluation of PD-L1 Schats et al
2 Table 1. Human Programmed Cell Death Ligand-1 (PD-L1) Immunohistochemistry (IHC) Assays and Applications PD-L1 Clone 22C SP142 SP263 Antibody host Mouse Rabbit Rabbit Rabbit Immunogen (Source: data sheet) Used in combination with therapeutic antibody (target) Commercial name therapeutic agent (Company) FDA-approved diagnostic IHC assay FDA-approved indications and, if applicable, cutoff for treatment (% PD-L1 þ cells) Human extracellular domain of PD-L1 (Phe19-Thr239) fused to a human IgG1 fragment Pembrolizumab (PD-1) Keytruda (MSD Inc, Kenilworth, New Jersey) Purified recombinant containing the extracellular domain (Phe19-Thr239) of human PD-L1 Synthetic peptide derived from the C-terminus of protein Nivolumab (PD-1) Atezolizumab (PD-L1) Durvalumab (PD-L1) Opdivo (BMS, New York, New York) Tecentriq (Genentech, South San Francisco, California) Synthetic peptide derived from the C-terminus of protein Imfinzi (AZ, Cambridge, United Kingdom) Nivolumab (PD-1) Opdivo (BMS, New York, New York) Pembrolizumab (PD-1) Keytruda (MSD Inc, Kenilworth, New Jersey) Companion Complementary Complementary Complementary Metastatic NSCLC NSCLC Metastatic NSCLC... NSCLC Metastatic NSCLC 50% TCs 1% TCs 50% TCs or 10% ICs Metastatic melanoma Melanoma % TCs Classical Hodgkin lymphoma Classical Hodgkin lymphoma MSI-H solid tumor HNSCC HNSCC % TCs Advanced urothelial bladder cancer Urothelial cancer Metastatic urothelial cancer Locally advanced or metastatic urothelial cancer % TCs 5% ICs 25% TCs or ICs... RCC Advanced gastric cancer HCC previously treated with sorafenib Abbreviations: AZ, AstraZeneca; BMS, Bristol Myers Squibb; FDA, US Food and Drug Administration; HCC, hepatocellular cancer; HNSCC, head and neck squamous cell cancer; ICs, immune cells; IgG1, immunoglobulin G1; MSD, Merck Sharp & Dohme; MSI-H, microsatellite instable high; NSCLC, non small cell lung cancer; PD-1, programmed cell death-1; Phe, phenylalanine; RCC, renal cell cancer; TCs, tumor cells; Thr, threonine. Arch Pathol Lab Med Vol 142, August 2018 Different Detection Methods for Evaluation of PD-L1 Schats et al 983
3 Table 2. Human Programmed Cell Death Ligand-1 (PD-L1) Immunohistochemistry (IHC) Assay Staining Protocols as Described in the Kit Insert PD-L1 Clone 22C SP142 SP263 Ab host Mouse Rabbit Rabbit Rabbit Immunogen (Source: data sheet) Human extracellular domain of PD-L1 (Phe19-Thr239) fused to a human IgG1 fragment Purified recombinant containing the extracellular domain (Phe19-Thr239) of Synthetic peptide derived from the C-terminus of protein Synthetic peptide derived from the C-terminus of protein Immunohistochemistry protocol kit insert Vendor kit Dako North America Inc, Ventana Medical Systems Inc, Tucson, Arizona Carpinteria, California IHC platform Autostainer Link 48 Ventana Benchmark Ultra HIER TRS low ph (ph 6.1) 48 min CC1 (ph 8.5) 64 min CC1 (ph 8.5) Blocking Peroxidase block Peroxidase block Ab concentration Prediluted in kit (ready to use) Ab incubation condition Room temperature, 30 min 368C, 16 min Amplification 30 min mouse linker 30 min rabbit linker 8 min amplification No Detection system 30 min dextran coupled with peroxidase OptiView molecules and GtARb and GtAMs immunoglobulins DAB enhancer 5 min... Abbreviations: Ab, antibody; CC, cell condition; DAB, 3,3 0 -diaminobenzidine; GtAMs, goat anti-mouse; GtARb, goat anti-rabbit; HIER, heatinduced epitope retrieval; IgG1, immunoglobulin G1; Phe, phenylalanine; Thr, threonine; TRS, target retrieval solution. samples were acquired from Bioreclamation IVT (Chestertown, Maryland). The comparison was performed on serial 4-lm slides to minimize the impact of biological variability. Immunohistochemistry All 4 PD-L1 PharmDx kits 22C3, 28-8 (both from Dako, Carpinteria, California); and SP142, SP263 (both from Ventana Medical Systems Inc, Tucson, Arizona) underwent an implementation validation on their assigned kit platform. Each staining run was qualified according to the guidelines described in the kit insert. Technical details of the PD-L1 kits are summarized in Table 2. Additionally, kit protocols were adapted by switching the detection methods (platform and IHC reagents; Table 3). In-house optimized and validated CD8 (C8/144B clone, Dako), CD163 (MRQ26 clone, Ventana Medical Systems), CD4 (1F6 clone, Leica Biosystems Richmond Inc, Richmond, Illinois), and CD68 (KP-1 clone, Ventana Medical Systems) IHC assays were performed on Ventana Benchmark XT platforms. The CD11c (5D11 clone, Leica Biosystems Richmond) IHC assay was Table 3. Human Programmed Cell Death Ligand-1 (PD-L1) Immunohistochemistry (IHC) Assays and Staining Protocols Using Another Detection System PD-L1 Clone 22C SP142 SP263 Ab host Mouse Rabbit Rabbit Rabbit Immunogen (Source: data sheet) Vendor primary antibody Human extracellular domain of PD-L1 (Phe19-Thr239) fused to a human IgG1 fragment Dako North America Inc, Carpinteria, California Purified recombinant containing the extracellular domain (Phe19-Thr239) of Immunohistochemistry adapted protocol Abcam, Cambridge, United Kingdom Synthetic peptide derived from the C-terminus of protein Spring Bioscience, Pleasanton, California Synthetic peptide derived from the C-terminus of protein IHC platform Ventana Benchmark XT Lab Vision Autostainer 480S HIER 64 min CC1 (ph 8.5) 30 min TRS (ph 9) Blocking Peroxidase block 3% hydrogen peroxide Ab concentration 1/50 in Dako antibody diluent with background-reducing components 1/75 in Ventana disco diluent 1/100 in Ventana disco diluent Ventana Medical Systems Inc, Tucson, Arizona 1/4 in Ventana disco diluent Ab incubation condition 368C, 60 min Room temperature, 60 min Amplification 8 min Ventana amplification 15 min Dako rabbit linker 15 min Dako rabbit linker Detection system Ventana OptiView 20 min Dako Flex Envision DAB enhancer... 5 min Abbreviations: Ab, antibody; CC, cell condition; DAB, 3,3 0 -diaminobenzidine; HIER, heat-induced epitope retrieval; IgG1, immunoglobulin G1; Phe, phenylalanine; Thr, threonine; TRS, target retrieval solution. 984 Arch Pathol Lab Med Vol 142, August 2018 Different Detection Methods for Evaluation of PD-L1 Schats et al
4 Figure 1. Overview of immunohistochemistry staining of serial sections in tonsil. Immune cell characterization (CD11c, CD68, CD163, CD4, and CD8) in tonsil deep crypt epithelium (A through E, respectively) and in germinal center (F through J, respectively). PD-L1 staining pattern using the kit protocols (22C3, 28-8, SP142, and SP263) in tonsil deep crypt epithelium (K through N, respectively) and germinal center (O through R, respectively). The staining pattern of PD-L1 with 22C3, 28-8, and SP263 kits is more macrophage-like in contrast to apparent lymphocyte staining by SP142 kit (insets) (original magnifications 35 [A through R]) and 360 [insets O through R]). Abbreviation: PD-L1, programmed death ligand-1. performed on a Lab Vision autostainer 480S (Thermo Scientific, Waltham, Massachusetts). PD-L1 IHC Evaluation All stained slides were scanned as whole slide images by using a digital slide scanner (3DHISTECH, Budapest, Hungary). The PD-L1 staining images were compared in identical regions of serial slides. A pathologist (24 years in practice), trained and qualified for scoring the PD-L1 assays, blinded for the applied protocol, scored the slides sequenarch Pathol Lab Med Vol 142, August 2018 tially for percentage of PD-L1 positive immune cells (ICs) and percentage of PD-L1 positive tumor cells (TCs). Only the membranous PD-L1 staining at all intensities was scored in the complete tumor area. Statistical Evaluation Statistical computations were performed with MedCalc (version , Ostend, Belgium). Spearman correlations (q) above 0.85 are considered as strong. Different Detection Methods for Evaluation of PD-L1 Schats et al 985
5 Figure 2. Comparison of PD-L1 immunohistochemistry staining patterns in NSCLC (A through D; I through L) and melanoma (E through H; M through P) tumor samples, using PD-L1 kits 22C3, 28-8, SP142, and SP263. High PD-L1 expression on TCs or ICs is equally detected in some cases (A through H). In other cases, sensitivity for TC or IC staining is different (I through P) (original magnifications 35 [A through H] and 310 [I through P]). Abbreviations: IC, immune cell; NSCLC, non small cell lung cancer; PD-L1, programmed death ligand-1; TC, tumor cell. RESULTS Implemented PD-L1 Kits Despite published validation details, all PD-L1 kits underwent an implementation validation. 3 5 The 22C3, 28-8, SP142, and SP263 PD-L1 kits demonstrate comparable staining of syncytiotrophoblasts in placenta, interferon c stimulated peripheral blood mononuclear cells, and Hodgkin lymphoma 2 (HDLM-2) cell pellets, while none stained the prostate cancer 3 (PC-3) cell pellets (supplementary Figure 1, A through T; see supplemental digital content, containing 2 figures at in the August 2018 table of contents). In tonsil (Figure 1, A through R), the deep crypt epithelium was positively stained with all assays but at different intensities (Figure 1, K through N). The SP263 assay, in particular, shows different intensity grades in contrast to the rather homogenous intensity of the 22C3, 28-8, and SP142 assays. As expected, all clones show dominant immunoreactivity in the germinal centers (Figure 1, O through R) and some scattered cells in the paracortical regions. However, within the germinal center there are differences in the number and cell types that are positively stained with each PD-L1 assay. The SP142 clone tends to stain a combination of macrophages/dendritic cells (positive for CD68 and CD11c, respectively) and lymphocytes (positive for CD4 and CD8). Contrarily, the 22C3, 28-8, and SP263 clones stain predominantly macrophage- or dendritic cell like cells (Figure 1, A through J). Within the tumor samples, some regions show strong immunoreactivity and similar staining patterns (TCs and/or ICs) with all 4 PD-L1 kits (Figure 2, A through H), while other regions show clear differences for TC and IC staining (Figure 2, I through P). The PD-L1 TC staining is not always detected with the SP142 assay, while it is clearly visible with the other assays (22C3, 28-8, SP263). Conversely, the SP142 assay tends to stain more ICs and with a sharper membrane delineation. The 22C3 and 28-8 assays show a less intense, fainter IC staining. Moreover, the dominant TC staining obtained with 22C3 and 28-8 assays seems to mask the intraepithelial PD-L1 positive ICs (Figure 2, I through L), rendering them difficult to distinguish. In accordance with these observations, a good correlation between the 22C3, 28-8, and SP263 kits was observed for TC as well as IC scoring (all q. 0.80) (supplementary Figure 2, A), while SP142 IC/TC correlations with the other kits were less than Arch Pathol Lab Med Vol 142, August 2018 Different Detection Methods for Evaluation of PD-L1 Schats et al
6 Figure 3. Comparison of PD-L1 staining pattern in deep crypt epithelium (A through D) and germinal center (E through H) of tonsil, stained with the PD-L1 kit protocol (A and B; E and F) and the adapted Linker þ Envision Flex (LþF) protocol (C and D; G and H) for both SP142 and SP263 (original magnification 35 [A through H]). Abbreviation: PD-L1, programmed death ligand-1. Adapted PD-L1 Detection Methods Lab Vision Staining Platform: Linker þ Envision Flex Detection. The SP142 and SP263 primary antibodies were tested on the Lab Vision staining platform using the Linker þ Envision Flex (LþF) detection method, which is used in the 22C3 and 28-8 kits. In tonsil (Figure 3, A through H), less intense IC and epithelial crypt staining is detected with the SP142 adapted protocol, while the opposite accounts for the SP263 adapted protocol. In tumor (Figure 4, A through P), as evident from Figure 4, C through P, the LþF detection method predisposed both the SP142 and SP263 kits toward detection of PD-L1 on TCs with the sharpest effect seen with SP142. The crisp IC staining with SP142 in its original kit format was no longer visible with the SP142 LþF detection method, because of improved PD-L1 TC staining, leading to shielding of the intratumoral PD-L1 positive ICs (Figure 4, A through N). The adapted SP142 assay resulted in TC and IC scoring more comparable with that of 28-8 and 22C3 kit assays (improved correlation; q approximately 0.8 for TCs and 0.9 for ICs). For SP263, the correlation with 28-8 and 22C3 scoring remained high for both TCs and ICs (q approximately 0.9) (supplementary Figure 2, B). Ventana Staining Platform: OptiView þ Amplification Detection. Pairing the Dako antibodies (22C3 and 28-8) with the Ventana OptiView þ Amplification (OþA) detection method remarkably improved the detection of PD-L1 on ICs (Figures 5, A through L; and 6, A through R). In both tonsil and tumor samples, a more and sharper delineated IC staining was observed. When compared with SP142 in particular, the IC correlation coefficients increased (supplementary Figure 2, C). On the other hand, the OþA application to the Dako antibodies did not alter TC staining. In addition, the effect of the amplification technology on the SP263 antibody was tested and showed an increased sensitivity of SP263 (Figure 6, C and F). DISCUSSION This pilot study aims to unravel the differences among the PD-L1 kits in order to assist pathology laboratories in diagnostic test selection, being either an alternative PD-L1 kit or laboratory-developed test. Unsurprisingly, we confirmed that 22C3, 28-8, SP142, and SP263 PD-L1 kits have different TC and IC sensitivities. The 4 PD-L1 IHC kits (22C3, 28-8, SP142, and SP263) revealed different IC staining patterns with 22C3, 28-8, and SP263 detecting more macrophage- and dendritic cell like cells, while SP142 identified more lymphocyte-like cells. The SP142 assay is clearly more sensitive for IC detection in tonsil and tumor. These results are in line with the publication of Scheel et al, 6 Adam et al, 7 and the FDA blueprint results. 8 In contrast, TCs are best detected with 22C3, 28-8, and SP263 kits. It is noteworthy that these differences in IC and/or TC sensitivity could not be observed on cell controls or placenta tissue (often suggested as staining control). Thus, validation of PD-L1 IHC staining requires additional inclusion of tonsil and tumor samples. Unexpectedly, the applied detection method (platform and IHC reagents) influences the identification of PD-L1 positive TCs or ICs and alludes to a major role of the detection method regardless of the PD-L1 antibody clone. Differences between the kits, for the most part, could be circumvented by switching to another detection method. The SP142 LþF protocol showed more TC staining than the kit insert and was more concordant with the 22C3 and 28-8 kits. The PD-L1 IC staining with the SP142 LþF assay also correlated better with both Dako kits, presumably because the increased TC staining shielded PD-L1 detection on the intratumor ICs. Our group 9 previously demonstrated that a Arch Pathol Lab Med Vol 142, August 2018 Different Detection Methods for Evaluation of PD-L1 Schats et al 987
7 Figure 4. Comparison of PD-L1 staining pattern (IC and TC staining) in identical regions of interest of tumor samples stained with the PD-L1 kit protocol (A through D) or the adapted Linker þ Envision Flex (LþF) protocol (E through H). In addition, the PD-L1 IC staining patterns were compared to CD8 (I through L) and CD163 (M through P) staining patterns (original magnification 310 [A through P]). Abbreviations: IC, immune cell; PD-L1, programmed death ligand-1; TC, tumor cell. sensitive detection method (eg, the OþA system) is needed for the detection of PD-L1 positive ICs. Thus, detection of PD-L1 on ICs in both tonsil and tumor specimens could now be observed with 22C3 and 28-8 antibodies when they were paired with the OþA detection method. In this configuration, both 22C3 and 28-8 retained their sensitivity for PD-L1 TC expression. Finally, when the SP263 antibody was paired with the OþA method, we noted an increase in the detection of PD-L1 on ICs. Many laboratories are accustomed to the assembly of their own laboratory-developed assays, each selecting its preferred antibodies and detection methods, based on available platforms and costs. 10 With PD-L1 IHC, this practice might create unintended results. To our knowledge, this pilot study shows for the first time that the detection method used in the PD-L1 IHC assay determines the staining pattern of a specific cell type or cellular compartment. Changing the detection method has important consequences on TC and/or IC sensitivity, affecting the clinical cutoff values and subsequently, patients PD-L1 positivity status. This study has shown that the different PD-L1 kits are not interchangeable. Therefore, it is recommended that the kits be used in accordance to their insert with proven clinical utility. Alternatively, when opting for an alternative PD-L1 kit or laboratory-developed test, these data stress comparison with the original kit for which clinical utility was established in combination with the therapeutic compound. Finally, optimal IC or TC detection may require different IHC detection methods; for instance, an LþF protocolfor sensitive TC detection and an OþA for sensitive IC detection. This obviously has broad implications for patient selection and warrants further investigation, in combination with the different scoring methods, to determine whether this approach might lead to an improved predictive value of the PD-L1 IHC assays for PD-1/PD- L1 targeted therapies. On the other hand, a single biomarker like PD-L1 might not be sufficient to predict response to immune therapy. There might be a need for multiple biomarkers to properly evaluate the complex tumor microenvironment. This project was funded by the IWT O&O grant No , awarded by the Agency for Innovation by Science and Technology (IWT) Belgium. 988 Arch Pathol Lab Med Vol 142, August 2018 Different Detection Methods for Evaluation of PD-L1 Schats et al
8 Figure 5. Comparison of the PD-L1 staining pattern in deep crypt epithelium (A through F) and germinal center (G through L) of tonsil, stained with PD-L1 kit protocol (A through C; G through I) and the adapted OptiView þ Amplification (OþA) protocol (D through F; J through L) for 22C3, 28-8, and SP263 (original magnification 35 [A through L]). Abbreviation: PD-L1, programmed death ligand-1. Arch Pathol Lab Med Vol 142, August 2018 Different Detection Methods for Evaluation of PD-L1 Schats et al 989
9 Figure 6. Comparison of the PD-L1 staining pattern (IC and TC staining) in identical regions of interest in tumor samples stained with PD-L1 kit protocol (A through C; M through O) versus the adapted OptiView þ Amplification (OþA) protocol (D through F; P through R). In addition, the PD- L1 IC staining patterns were compared to the CD8 (G through I) and CD163 (J through L) staining patterns (original magnification 35 [A through R]). Abbreviations: IC, immune cell; PD-L1, programmed death ligand-1; TC, tumor cell. 990 Arch Pathol Lab Med Vol 142, August 2018 Different Detection Methods for Evaluation of PD-L1 Schats et al
10 References 1. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1 positive non small-cell lung cancer. N Engl J Med. 2016;375(19): Rosenberg JE, Hoff J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 387(10031): Roach C, Zhang N, Corigliano E, et al. Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-small-cell lung cancer. Appl Immunohistochem Mol Morphol. 2016;24(6): Rebelatto MC, Midha A, Mistry A, et al. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of nonsmall cell lung cancer and head and neck squamous cell carcinoma. Diagn Pathol. 2016;11(1): Phillips T, Simmons P, Inzunza HD, et al. Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. Appl Immunohistochem Mol Morphol. 2015;23(8): Scheel AH, Dietel M, Heukamp LC, et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol. 2016;29(10): Adam J, Rouquette I, Damotte D, et al. PL04a.04: Multicentric French Harmonization study for PD-L1 IHC testing in NSCLC. J Thorac Oncol. 2017; 12(1):S11 S Hirsch FR, Mcelhinny A, Stanforth D, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol. 2017;12(2): Schats KA, Van Vré EA, De Schepper S, et al. Validated PD-L1 immunohistochemistry assays (E1L3N and SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system. Histopathology. 2017;70(2): Yaziji H, Taylor CR. PD-L1 assessment for targeted therapy testing in cancer: urgent need for realistic economic and practice expectations. 2017;25(1):1 3. Arch Pathol Lab Med Vol 142, August 2018 Different Detection Methods for Evaluation of PD-L1 Schats et al 991
Assessment Run C1 2017
Assessment Run C1 2017 PD-L1 The first assessment in this new NordiQC Companion module C1 focused on the accuracy of the PD-L1 IHC assays performed by the participating laboratories to identify patients
More informationAssessment Run C3 2018
Assessment Run C3 2018 PD-L1 Amended version May 14 th 2018 The third assessment in NordiQC Companion module C3 focused on the accuracy of the PD-L1 IHC assays performed by the participating laboratories
More informationImmunotherapy in NSCLC Pathologist role
Immunotherapy in NSCLC Pathologist role Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in NSCLC Khono et al, Trans Lung
More informationLung cancer PD-L1 testing clinical impact
Lung cancer PD-L1 testing clinical impact Korinna Jöhrens Institute for pathology Carl Gustav Cars Universitätsklinikum Dresden, Germany Medical consultant QuIP Immune therapy with checkpoint-inhibitors
More informationHistopathology 2016 DOI: /his.13056
Histopathology 216 DOI:.1111/his.1356 Validated programmed cell death ligand 1 immunohistochemistry assays ( and SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive
More informationEstrogen receptor (ER)
Material The slide to be stained for ER comprised: Assessment Run B26 2018 Estrogen receptor (ER) No. Tissue ER-positivity* ER-intensity* 1. Uterine cervix 80-90% Moderate to strong 2. Tonsil 1-5% Weak
More informationSupplementary Online Content
Supplementary Online Content Rimm DL, Han G, Taube JM, et al. A prospective, multi-institutional, pathologistbased assessment of 4 immunohistochemistry assays for PD-L1 expression in non small cell lung
More informationPredictive markers for treatment with Immune checkpoint inhibitors - PD-L1 et al -
Predictive markers for treatment with Immune checkpoint inhibitors - PD-L1 et al - Lukas Bubendorf Pathology Improved overall survival as a result of combination therapy Predictive biomarkers for the treatment
More informationNSCLC. Harmonization study 1. Lung cancer and other malignancies -PD-L1 assay, QuIP EQA
Lung cancer and other malignancies -PD-L1 assay, QuIP EQA Korinna Jöhrens Institute for pathology Carl Gustav Cars Universitätsklinikum Dresden, Germany Medical consultant QuIP 11.05.2018 NSCLC Harmonization
More informationEstrogen receptor (ER)
Material The slide to be stained for ER comprised: Assessment B25 208 Estrogen receptor (ER) No. Tissue ER-positivity* ER-intensity*. Uterine cervix 80-90% Moderate to strong 2. Tonsil < 2-5% Weak to strong
More informationRole of the Pathologist in Guiding Immuno-oncological Therapies. Scott Rodig MD, PhD
Role of the Pathologist in Guiding Immuno-oncological Therapies Scott Rodig MD, PhD Department of Pathology, Brigham & Women s Hospital Center for Immuno-Oncology, Dana-Farber Cancer Institute Associate
More informationReview of NEO Testing Platforms. Lawrence M. Weiss, MD Medical Director, Aliso Viejo
Review of NEO Testing Platforms Lawrence M. Weiss, MD Medical Director, Aliso Viejo Lawrence Weiss, M.D. Medical Director, Aliso Viejo Dr. Weiss currently serves as NeoGenomics Medical Director, Aliso
More informationResults you can trust
PRODUCT I NF OR MAT ION pharmdx Results you can trust The first and only FDA-approved PD-L1 test to assess the magnitude of treatment effect on progression-free survival in melanoma patients from OPDIVO
More informationEstrogen receptor (ER)
Assessment Run B7 204 Estrogen receptor (ER) Material The slide to be stained for ER comprised: No. Tissue ER-positivity* ER-intensity*. Uterine cervix 80-90% Moderate to strong 2. Breast carcinoma 0%
More informationVernieuwing en diagnostiek bij NSCLC: Immunotherapy: PD-L1 analyse: waar staan we
9e avondsymposium: "Nieuwe ontwikkelingen in de behandeling van NSCLC" 9 november 2016, UMCG Vernieuwing en diagnostiek bij NSCLC: Immunotherapy: PD-L1 analyse: waar staan we Wim Timens Professor and Chair
More informationAgilent companion diagnostics for cancer immunotherapy
Agilent companion diagnostics for cancer immunotherapy Annika Eklund, PhD Global Product Manager Companion Diagnostics Agilent Technologies Aalborg 1 Agilent Trusted Answers. Together OUR FOCUS life sciences,
More informationAssessment Run
Assessment Run 50 2017 S100 Material The slide to be stained for S100 comprised: 1. Appendix, 2. Tonsil, 3. Schwannoma, 4-5. Malignant melanoma, 6. Colon adenocarcinoma. All tissues were fixed in 10% neutral
More informationAssessment Run GATA3
Assessment Run 44 2015 GATA3 Material The slide to be stained for GATA3 comprised: 1. Tonsil 2. Kidney, 3. Urothelial carcinoma, 4. Breast ductal carcinoma, 5. Colon adenocarcinoma All tissues were fixed
More informationPD-L1 and Immunotherapy of GI cancers: What do you need to know
None. PD-L1 and Immunotherapy of GI cancers: What do you need to know Rondell P. Graham September 3, 2017 2017 MFMER slide-2 Disclosure No conflicts of interest to disclose 2017 MFMER slide-3 Objectives
More informationBiomarkers for Cancer Immunotherapy Debate
Biomarkers for Cancer Immunotherapy Debate Moderator: Maria Karasarides, PhD AstraZeneca Pro: Daniel S. Chen, MD, PhD Genentech Con: Steve Averbuch, MD Bristol-Myers Squibb Biomarkers to Select Patients
More informationAnti-PD-L1 antibody [28-8] ab205921
Anti-PD-L1 antibody [28-8] ab205921 2 Abreviews 16 References 15 Images Overview Product name Anti-PD-L1 antibody [28-8] Description Tested applications Species reactivity Immunogen Rabbit monoclonal [28-8]
More informationPredictive Biomarkers for Pembrolizumab. Eric H. Rubin, M.D.
Predictive Biomarkers for Pembrolizumab Eric H. Rubin, M.D. PD-1 and PD-L1/L2 Pathway PD-1 is an immune checkpoint receptor Binding of PD-1 by its ligands PD-L1 or PD-L2 leads to downregulation of T-cell
More informationEpithelial cell-cell adhesion molecule (Ep-CAM)
Assessment Run 3 011 Epithelial cell-cell adhesion molecule (Ep-CAM) Material The slide to be stained for Ep-CAM comprised: 1. Appendix,. Kidney, 3. Adrenal gland, 4. Lung carcinoid, 5 & 6. Renal clear
More informationInterpretation Manual - Gastric or Gastroesophageal Junction Adenocarcinoma. PD-L1 IHC 22C3 pharmdx is FDA-approved for in vitro diagnostic use
Interpretation Manual - Gastric or Gastroesophageal Junction Adenocarcinoma PD-L1 IHC 22C3 pharmdx is FDA-approved for in vitro diagnostic use For countries outside of the United States, see the local
More informationSMH (Myosin, smooth muscle heavy chain)
Material The slide to be stained for SMH comprised: Assessment Run 50 2017 SMH (Myosin, smooth muscle heavy chain) 1.Tonsil, 2. Esophagus, 3. Breast hyperplasia, 4. Breast ductal carcinoma in situ (DCIS),
More informationVENTANA PD-L1 (SP142) Assay Guiding immunotherapy
VENTANA PD-L1 (SP142) Assay Guiding immunotherapy Hiker s path: VENTANA PD-L1 (SP142) Assay on urothelial carcinoma tissue Location: Point Conception, CA VENTANA PD-L1 (SP142) Assay Identify patients most
More informationVENTANA PD-L1 (SP142) Assay Guiding immunotherapy in NSCLC
VENTANA (SP142) Assay Guiding immunotherapy in NSCLC Hiker s path: VENTANA (SP142) Assay on non-small cell lung cancer tissue Location: Point Conception, CA VENTANA (SP142) Assay Assess NSCLC patient benefit
More informationAdvances in Pathology and molecular biology of lung cancer. Lukas Bubendorf Pathologie
Advances in Pathology and molecular biology of lung cancer Lukas Bubendorf Pathologie Agenda The revolution of predictive markers Liquid biopsies PD-L1 Molecular subtypes (non-squamous NSCLC) Tsao AS et
More informationCarcinoembryonic antigen (CEA)
Assessment Run 37 2013 Carcinoembryonic antigen (CEA) Material The slide to be stained for CEA comprised: 1. Appendix, 2. Liver, 3-4. Colon adenocarcinoma, 5. Urothelial carcinoma All tissues were fixed
More informationVENTANA PD-L1 (SP142) Assay
VENTANA (SP142) Assay Guiding immunotherapy Hiker s path: VENTANA (SP142) Assay on urothelial carcinoma tissue Location: Point Conception, CA VENTANA (SP142) Assay Assess UC patient benefit from TECENTRIQ
More informationThe Role of Immuno-Oncology Biomarkers in Lung Cancer
The Role of Immuno-Oncology Biomarkers in Lung Cancer Vamsidhar Velcheti, MD, FACP Staff Physician, Associate Director Center for Immuno-Oncology Research Taussig Cancer Institute Cleveland Clinic November
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: November 30, 2018 Keytruda Description Keytruda
More informationLung Anaplastic Lymphoma Kinase (lu-alk)
Assessment Run 5 207 Lung Anaplastic Lymphoma Kinase (lu-alk) Material The slide to be stained for lu-alk comprised:. Appendix, 2. Tonsil, 3. Merkel cell carcinoma, 4. Anaplastic large cell lymphoma with
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationPatient Selection: The Search for Immunotherapy Biomarkers
Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic
More informationPD-L1 Expression, Role, and Significance in Lung Pathology. Ross A Miller, MD FACP FASCP
PD-L1 Expression, Role, and Significance in Lung Pathology Ross A Miller, MD FACP FASCP Background information PD-1 and PD-L1 expression in tissues PD-L1 Ligand to PD-1 (PD-1 on T cells) Rarely expressed
More informationEARLY ONLINE RELEASE
EARLY ONLINE RELEASE Note: This article was posted on the Archives Web site as an Early Online Release. Early Online Release articles have been peer reviewed, copyedited, and reviewed by the authors. Additional
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: September 20, 2018 Keytruda Description Keytruda
More informationCytokeratin 19 (CK19)
Assessment Run 34 202 Cytokeratin 9 (CK9) Material The slide to be stained for CK9 comprised:. Thyroid gland, 2. Appendix, 3. Esophagus, 4. Papillary thyroid carcinoma, 5 & 6. Pancreatic neuroendocrine
More informationCarcinoma Urotelial: La Célula Inflamatoria Clave en la Inmunoterapia Fernando López-Ríos
Carcinoma Urotelial: La Célula Inflamatoria Clave en la Inmunoterapia Fernando López-Ríos Laboratorio de Dianas Terapéuticas Hospital Universitario HM Sanchinarro Madrid, Spain Contents Background Immunotherapy
More informationICLIO National Conference
ICLIO National Conference Immuno-oncology In The Clinic Today Lee Schwartzberg, MD, FACP Executive Director, West Cancer Center Chief, Division of Hematology/Oncology University of Tennessee Health Science
More informationMICROSCOPY PREDICTIVE PROFILING
Immunomodulatory therapy in NSCLC: a year into clinical practice Professor J R Gosney Consultant Thoracic Pathologist Royal Liverpool University Hospital Disclosure JRG is a paid advisor to and speaker
More informationAssessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer
Original Article Assessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer Chen Pang 1 *, Limei Yin 1 *, Xiaojuan Zhou 1 *,
More informationThyroid transcription factor-1 (TTF1) Assessment run
Thyroid transcription factor- (TTF) Assessment run 39 203 The slide to be stained for TTF comprised:. Thyroid gland, 2. Liver, 3. Normal lung, 4. Lung adenocarcinoma 5. Colon adenocarcinoma, 6 & 7. Lung
More informationAssessment Run CK19
Assessment Run 29 200 CK9 The slide to be stained for CK9 comprised:. Appendix, 2. Thyroid gland, 3. Pancreas, 4. Ductal breast carcinoma, 5. Esophagus, 6. Papillary thyroid carcinoma. All tissues were
More informationConsistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay
Scorer et al. Diagnostic Pathology (2018) 13:47 https://doi.org/10.1186/s13000-018-0725-9 RESEARCH Open Access Consistency of tumor and immune cell programmed cell death ligand-1 expression within and
More informationAssessment Run B HER-2 IHC. HER-2/chr17 ratio**
Assessment Run B2 20 HER-2 IHC Material The slide to be stained for HER-2 comprised the following 5 tissues: IHC HER-2 Score* (0, +, 2+,3+) FISH HER-2/chr7 ratio**. Breast ductal carcinoma 0..3 2. Breast
More informationAssessment Run B HER2 IHC
Assessment Run B24 2017 HER2 IHC Material The slide to be stained for HER2 comprised the following 5 materials: IHC: HER2 Score* (0, 1+, 2+, 3+) FISH: HER2 gene/chr 17 ratio** 1. Breast carcinoma, no.
More informationAssessment Run B HER2 IHC
Assessment Run B26 208 HER2 IHC Material The slide to be stained for HER2 comprised the following 5 materials: IHC: HER2 Score* (0, +, 2+, 3+) FISH: HER2 gene/chr 7 ratio**. Breast carcinoma, no. 2+..3
More informationSal-like protein 4 (SALL4)
Assessment Run 43 205 Sal-like protein 4 (SALL4) The slide to be stained for SALL4 comprised:. Appendix, 2. Testis, 3. Renal clear cell carcinoma, 4. Seminoma, 5. Intratubular germ cell neoplasia (IGCN),
More informationProgrammed death ligand-1 (PD-L1) protein expression
Original Articles Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer Karina Kulangara, PhD; Nancy
More informationStrengths and Weaknesses of PD-L1 testing: Pathology perspective
Strengths and Weaknesses of PD-L1 testing: Pathology perspective Prof Keith M Kerr Department of Pathology Aberdeen University Medical School, Aberdeen Royal Infirmary Foresterhill, Aberdeen Disclosures
More informationLung Cancer Update on Pathology Zhaolin Xu, MD, FRCPC, FCAP
Lung Cancer Update on Pathology Zhaolin Xu, MD, FRCPC, FCAP Professor, Dept of Pathology, Dalhousie University Pulmonary Pathologist and Cytopathologist, QEII HSC Senior Scientist, Beatrice Hunter Cancer
More informationInnovation, Uncertainty and Reimbursement Processes in Precision Medicine: The Case of PD-L1
Innovation, Uncertainty and Reimbursement Processes in Precision Medicine: The Case of PD-L1 Monday, October 17, 2016 MaRS Discovery District, Toronto This session was generously sponsored by Merck Canada
More informationEl contexto molecular de la sobreexpresión de PD-L1 Esther Conde Gallego, MD, PhD
El contexto molecular de la sobreexpresión de PD-L1 Esther Conde Gallego, MD, PhD Laboratorio de Dianas Terapéuticas Hospital Universitario HM Sanchinarro Madrid, Spain Contents Background PD-L1 expression
More informationO DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal. Gabriela Sousa Oncologia Médica IPO Coimbra
O DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal Gabriela Sousa Oncologia Médica IPO Coimbra Incidência aumenta 3% ao ano Envelhecimento populacional
More informationEmerging Tissue and Serum Markers
Emerging Tissue and Serum Markers for Immune Checkpoint Inhibitors Kyong Hwa Park MD, PhD Medical Oncology Korea University College of Medicine Contents Immune checkpoint inhibitors in clinical practice
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationEmerging biomarkers for immunotherapy in lung cancer
Emerging biomarkers for immunotherapy in lung cancer Prof Keith M Kerr Department of Pathology Aberdeen University Medical School, Aberdeen Royal Infirmary Aberdeen, UK Why Do We Need Biomarkers for Immunotherapy?
More informationSingle and Multiplex Immunohistochemistry
Single and Multiplex Immunohistochemistry Steve Westra, BS Reagent Product Specialist Leica Biosystems IHC Theory Polyclonal vs Monoclonal Polyclonal reagents Detect a multitude of epitopes Batch to batch
More informationDevelopment of a Companion Diagnostic for Pembrolizumab in Non Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1
Development of a Companion Diagnostic for Pembrolizumab in Non Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1 Marisa Dolled-Filhart, PhD; Charlotte Roach, BS; Grant Toland,
More informationImmunotherapie: algemene principes
Immunotherapie: algemene principes Prof. dr. Evelien Smits Tumorimmunologie, UAntwerpen 14 Oktober 2017, IKG evelien.smits@uza.be Concept of immune evasion Finn O. J. Ann Oncol. 2012 Sep; 23(Suppl 8):
More informationAssessment Run NKX3.1 (NKX3.1)
Assessment Run 49 2017 NKX3.1 (NKX3.1) Material The slide to be stained for NKX3.1 comprised: 1. Testis 2. Appendix 3-4. Prostate adenocarcinoma 5. Prostate hyperplasia All tissues were fixed in 10% neutral
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 7 Last Review Date: December 8, 2017 Keytruda Description Keytruda
More informationIMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER
IMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER A guide for patients and caregivers TM Content is consistent with the Oncology Nursing Society Standards and Guidelines. The ONS Seal of Approval does not
More informationHistology independent indications in Oncology
CHMP Oncology Working Party Workshop Histology independent indications in Oncology What have we learnt from the anti PD1- PDL1 story? J Camarero (CHMP alternate ES, OncWP) Disclaimers the views presented
More informationCancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015
Cancer Immunotherapy Patient Forum for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015 Biomarkers and Patient Selection Julie R. Brahmer, M.D. Director
More informationGetting the Whole Picture for Immuno-Oncology Therapies
Joseph Krueger, Chief Scientific Officer, Flagship Biosciences, Inc. Getting the Whole Picture for Immuno-Oncology Therapies Key concepts: Immuno-oncology (IO) therapies have changed the way we think about
More informationBiomarcatori per la immunoterapia: cosa e come cercare Paolo Graziano
Biomarcatori per la immunoterapia: cosa e come cercare Paolo Graziano Unit of Pathology Fondazione IRCCS Casa Sollievo della Sofferenza San Giovanni Rotondo, Foggia,Italy p.graziano@operapadrepio.it Disclosure
More informationWe re Reaching Ludicrous Speed: New Immunotherapy Oncology Medications
We re Reaching Ludicrous Speed: New Immunotherapy Oncology Medications Adam Peele, PharmD, BCPS, BCOP Oncology Pharmacy Manager Cone Health Disclosures Merck Pharmaceuticals Speaker s Bureau 1 Objectives
More informationPolicy. Medical Policy Manual Approved Revised: Do Not Implement Until 3/2/19. Nivolumab (Intravenous)
Nivolumab (Intravenous) NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3734-XX Opdivo 240
More informationOptimization of antibodies, selection, protocols and controls Breast tumours
Optimization of antibodies, selection, protocols and controls Breast tumours Søren Nielsen Project coordinator & Scheme Manager NordiQC Aalborg University Hospital, Denmark Breast panel: GCDFP-15 Mammaglobin
More informationPolicy. Medical Policy Manual Approved Revised: Do Not Implement until 6/30/2019. Nivolumab
Medical Manual Approved Revised: Do Not Implement until 6/30/2019 Nivolumab NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB
More informationEnterprise Interest Lecture 9º Personalized Healthcare in Oncology sponsored by Roche, Lisbon 2017 Bladder Diagnostic Advisory Board Invitation
Enterprise Interest Lecture 9º Personalized Healthcare in Oncology sponsored by Roche, Lisbon 2017 Bladder Diagnostic Advisory Board Invitation sponsored by Astra-Zeneca, London 2017 SPEC-02 ESP/ESMO PD-L1
More informationThe Challenges of Implementing a PD-L1 Proficiency Testing Program in Australia
VASCULAR CELL OPEN ACCESS ORIGINAL RESEARCH The Challenges of Implementing a PD-L1 Proficiency Testing Program in Australia Pagliuso Julia, Parry Suzanne, Haffajee Zenobia, Badrick Tony, Miller Keith,
More informationMolecular Testing in Lung Cancer
Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor
More informationProduct Introduction. Product Codes: HCL029, HCL030 and HCL031. Issue
Product Introduction Product Codes: HCL029, HCL030 and HCL031 Issue 1. 180510 Contents Introduction to Estrogen Receptor 2 ER immunohistochemistry 3 Quality control 5 Cell lines as controls 6 Estrogen
More informationTITLE: UK NEQAS ICC & ISH Pre-Pilot Meeting for PD-L1. Immunohistochemistry in Non-Small Cell Lung Carcinoma
TITLE: UK NEQAS ICC & ISH Pre-Pilot Meeting for PD-L1 Immunohistochemistry in Non-Small Cell Lung Carcinoma Ms Amy Newman, Ms Suzanne Parry, Mrs Dawn Wilkinson, Dr Tony O Grady, Dr Perry Maxwell, Mr David
More informationCorporate presentatie Maastricht UMC+ (titel presentatie)
Datum Corporate presentatie Maastricht UMC+ (titel presentatie) PDL1: een simpele kleuring? Titel Naam spreker van (optioneel) de presentatie Functie spreker (optioneel) Onderwerpregel Ernst Jan M. Speel,
More informationVENTANA PD-L1 (SP263) Assay Staining in Urothelial Carcinoma Interpretation Guide
VENTANA PD-L1 (SP263) Assay Staining in Urothelial Carcinoma Interpretation Guide 2 VENTANA PD-L1 (SP263) Assay in Urothelial Carcinoma Interpretation Guide Table of Contents Introduction 4 Intended Use
More informationJohn Cogswell 1 H. David Inzunza. Gabe Mintier 1 James Novotny
Mol Diagn Ther (2017) 21:85 93 DOI 10.1007/s40291-016-0237-9 ORIGINAL RESEARCH ARTICLE An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical
More informationCancer Immunotherapy Survey
CHAPTER 8: Cancer Immunotherapy Survey All (N=100) Please classify your organization. Academic lab or center Small biopharmaceutical company Top 20 Pharma Mid-size pharma Diagnostics company Other (please
More informationOpdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic Agents Original Policy Date: January 16, 2015 Subject: Opdivo Page:
More informationUrothelial Carcinoma (UC)
EDUCATION PD-L1 IHC 28-8 pharmdx Interpretation Manual Urothelial Carcinoma (UC) For In Vitro Diagnostic Use Table of Contents Introduction...5 Intended Use in Urothelial Carcinoma...5 How to Use the
More information(generic name: ipilimumab) Injection 50 mg ( Yervoy ), a human anti-human CTLA-4 monoclonal. August 21, 2018
August 21, 2018 Opdivo Approved for Supplemental Applications for Expanded Indications of Malignant Pleural Mesothelioma and Adjuvant Treatment of Melanoma, Change in Dosage and Administration (D&A) of
More informationRole of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney
Role of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney Consultant Thoracic Pathologist Royal Liverpool University Hospital Disclosure JRG is a paid advisor
More informationGLOBAL REGISTRATION STRATEGIES:
GLOBAL REGISTRATION STRATEGIES: Therapeutic Product (TP) and the Companion Diagnostic (CDx) Erin Pedalino Regulatory Affairs International MSD Unique Role as CDx Regulatory Liaison at a Therapeutic Product
More informationNews from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital
News from ASCO Niven Mehra, Medical Oncologist Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital Disclosures Speaker fees: Merck, Bayer Advisory boards: Janssen-Cilag Research and
More informationCompanion & Complementary Diagnostics: Clinical and Regulatory Perspectives
Companion & Complementary Diagnostics: Clinical and Regulatory Perspectives Workshop on Companion Diagnostics January 31, 2017 Jan Trøst Jørgensen, M.Sc.Pharm., Ph.D. Dx-Rx Institute Fredensborg, Denmark
More informationPATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER
PATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER Martin Reck Department of Thoracic Oncology LungClinic Grosshansdorf Germany DISCLOSURES Honoraria for
More informationPD-L1 Analyte Control DR
Quality in Control PD-L1 Analyte Control DR PD-L1_PI_v2 Product Codes: HCL019, HCL020 and HCL021 Contents PD-L1 Analyte Control DR 2 What is PD-L1? 3 The Role of PD-L1 in Cancer 3 PD-L1 Assessment 4 PD-L1
More informationDiagnostic & Predictive Immunohistochemistry in Lung Carcinomas
Diagnostic & Predictive Immunohistochemistry in Lung Carcinomas Lynette M. Sholl, M.D. Associate Pathologist, Brigham and Women s Hospital Associate Professor, Harvard Medical School Boston, MA Disclosures
More informationProduct Introduction
Product Introduction Product Codes: HCL026, HCL027 and HCL028 Contents Introduction to HER2 2 HER2 immunohistochemistry 3 Cell lines as controls 5 HER2 Analyte Control DR IHC 7 HER2 Analyte Control DR
More informationDevelopment of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Gong et al. Journal for ImmunoTherapy of Cancer (2018) 6:8 DOI 10.1186/s40425-018-0316-z REVIEW Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration
More informationAssessment performed on Friday, September 18, 2015, at Vancouver General Hospital
Assessors report for ciqc Run 49: ATRX (June 2015) Assessors: S Yip and J Won (recorder) Assessment performed on Friday, September 18, 2015, at Vancouver General Hospital Background The combined application
More informationPolicy #: 668 Effective Date: December 1, 2016 Category: Pharmacology Latest Review Date: September 2016
Name of Policy: Tecentriq (Atezolizumab) Policy #: 668 Effective Date: December 1, 2016 Category: Pharmacology Latest Review Date: September 2016 Background/Definitions: As a general rule, benefits are
More information